Coherus Oncology Inc Dossier - Source-backed chat

Coherus Oncology Inc

CHRSNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.96

Intrinsic Value $2.09median of 2 methodsbased on filings through 30 Jun 2026

Market Price $1.16Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 81% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+81%)

Data confidence Sign in to view data confidence

Market Cap $179.2M

Enterprise Value $133.3M

Shares Outstanding 146.8M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Coherus Oncology, Inc. (formerly Coherus BioSciences, Inc.) has successfully completed its strategic pivot from a biosimilar developer to a pure-play innovative immuno-oncology company. This transition was solidified by the divestiture of its UDENYCA franchise, which significantly reduced its debt profile by over 90%. The company's commercial foundation is anchored by LOQTORZI (toripalimab-tpzi), the only FDA-approved PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma (NPC). While LOQTORZI provides a steady commercial baseline with a projected $175 million annualized target by 2028, the near-term valuation is heavily geared toward its proprietary combination pipeline. Key clinical catalysts in mid-to-late 2026—specifically Phase 2 data for the IL-27 antagonist casdozokitug in liver cancer and Phase 1b data for the anti-CCR8 antibody tagmokitug (CHS-114) in solid tumors—represent high-asymmetric upside opportunities. Backed by a strengthened cash position of $167 million, Coherus is well-positioned to reach these critical inflection points.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$4.00

Mean target$7.80

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0520%

LOQTORZI sales plateau due to the niche nature of the NPC market and intense competition from established PD-1 inhibitors in off-label settings, failing to reach the $15 million quarterly target. The Phase 2 trial for casdozokitug fails to show a meaningful clinical benefit over the standard-of-care atezolizumab/bevacizumab doublet, or exhibits limiting toxicities. Tagmokitug's early data is ambiguous or fails to translate Treg depletion into clinical efficacy. With a high cash burn rate, the company is forced to execute a highly dilutive equity financing round to extend its runway.

Base CaseCentral scenario

$7.8055%

Matches the consensus mean

LOQTORZI continues its steady sequential growth, meeting the projected $15 million quarterly run rate in late 2026 as seasonal headwinds subside. The Phase 2 casdozokitug data in first-line uHCC shows a positive therapeutic signal and a competitive safety profile, confirming its role as a viable combination partner for toripalimab. Tagmokitug's Phase 1b readouts in HNSCC and gastric cancer confirm selective Treg depletion and immune activation, keeping both pipeline assets on track for further mid-stage development and supporting a gradual upward re-rating of the stock.

Bull CaseUpside scenario

$12.0025%

LOQTORZI commercial adoption accelerates rapidly, exceeding the $15 million quarterly milestone in 2026 through successful market penetration and displacement of chemotherapy-only regimens. Simultaneously, the Phase 2 uHCC trial for casdozokitug delivers outstanding efficacy data, demonstrating a statistically superior objective response rate (ORR) and progression-free survival (PFS) for the triplet combination. This triggers a lucrative global co-development partnership with a major pharmaceutical peer, bringing in substantial upfront non-dilutive cash. Tagmokitug also showcases robust, selective intratumoral Treg depletion with a clean safety profile, establishing it as a best-in-class CCR8 candidate.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Exclusive FDA-approved position for LOQTORZI in nasopharyngeal carcinoma, serving as a stable commercial foundation and a proprietary PD-1 backbone for pipeline combinations.
Substantial balance sheet improvement following the divestiture of the biosimilar business, reducing secured and convertible debt by over 90% from $480 million to $38.8 million.
Highly innovative, first-in-class oncology pipeline assets (casdozokitug and tagmokitug) targeting novel immune-suppressive pathways with major readouts in mid-2026.
Strong cash position of $167 million as of Q1 2026, bolstered by a successful $54 million follow-on equity offering, providing runway through key clinical milestones.

Key Investment Risks

High clinical development risk inherent to early and mid-stage oncology assets, where positive translational data may not translate to clinical efficacy.
Commercial concentration risk, as the company currently relies on a single approved product (LOQTORZI) in a niche orphan indication.
Significant ongoing operating losses ($36.9 million GAAP net loss in Q1 2026) and high cash burn, which could necessitate future dilutive capital raises if clinical milestones are delayed.
Intense competition in the broader immuno-oncology space from well-capitalized global pharmaceutical companies with established PD-1/PD-L1 franchises.

Thesis Invalidation Triggers

Failure of the Phase 2 casdozokitug combination trial in first-line uHCC to meet its efficacy endpoints or show a clear benefit over standard doublet therapy.
A severe sequential decline or stagnation in LOQTORZI net sales, indicating a lower-than-expected market ceiling in the NPC indication.
Safety signals or severe adverse events in the tagmokitug (CHS-114) clinical program that halt development.
Rapid depletion of cash reserves leading to an unexpected, highly dilutive equity offering prior to the release of major clinical data.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.